NanoPass Technologies Ltd. is a pioneer in intradermal delivery, leveraging its proprietary MicronJet™ platform, the first FDA-cleared true intradermal delivery technology (less than 1 mm), to transform treatments across both medical and aesthetic fields.

With over 70 clinical studies and millions of successful procedures worldwide, the company is at the forefront of advancing vaccines, immunotherapies, and drug delivery, enabling proven dose-sparing and improved patient outcomes. In parallel, NanoPass has brought its innovation to the aesthetic landscape, where MicronJet™ provides physicians and patients with a new standard of safety, precision, and comfort, minimizing bruising, pain, and downtime while enabling consistent delivery of skin boosters, polynucleotides, PDRN, Lidocaine, PRP, and other intradermal treatments.

Today, NanoPass operates globally in more than 30 countries, partnering with leading pharmaceutical and aesthetic brands.